Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Zalicus Compound Fails in Phase II | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Zalicus Compound Fails in Phase II

Chronic pain treatment Z160 cancelled, company to focus on Z944

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Zalicus posted disappointing top-line results from two Phase II studies of Z160 in chronic pain indications. Z160 did not meet the primary endpoint in either study in patients with lumbosacral radiculopathy (LSR) and post-herpetic neuralgia (PHN).

Z160 was shown to be generally safe and well-tolerated with no drug-related serious adverse events. Based on these results, Zalicus is discontinuing the Z160 program and plans to focus efforts on Z944, its novel oral T-type calcium channel modulator in development for the treatment of pain.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics